人福醫藥(600079.SH):宜昌人福獲英國GMP證書
格隆匯8月23日丨人福醫藥(600079.SH)公佈,近日,公司控股子公司宜昌人福藥業有限責任公司(以下簡稱“宜昌人福”,公司持有其67%的股權)收到英國藥品與健康產品管理局(以下簡稱MHRA)頒發的GMP證書。
本次認證所涉及的生產線為宜昌人福位於宜昌市遠安縣鳴鳳路的口服固體制劑車間,年設計產能為50億片片劑、10億粒膠囊、1億袋顆粒、1億袋散劑,相關廠房設備等固定資產累計投入約為2.84億元,於2015年獲得中國GMP認證並投入運營。2018年該車間生產片劑78,104.42萬片,膠囊劑9143.38萬粒,顆粒劑1711.93萬袋,散劑265.16萬袋,共計實現銷售收入1.27億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.